<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175707</url>
  </required_header>
  <id_info>
    <org_study_id>3009-009</org_study_id>
    <secondary_id>DAP-4HOME-09-05</secondary_id>
    <nct_id>NCT01175707</nct_id>
  </id_info>
  <brief_title>Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting</brief_title>
  <official_title>A Phase 4, Prospective, Randomized, Open-label Study to Compare Use of Cubicin With Vancomycin Administered Intravenously in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Confirmed Gram-positive Bacteria in a Home Infusion Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multi-center, phase 4 study designed to compare intravenous
      (IV) daptomycin and IV vancomycin administered in a home infusion setting for the treatment
      of complicated skin and skin structure infections (cSSSI) due to Gram-positive bacteria in
      participants who are prescribed vancomycin for 7 to 14 days and who are planning to receive
      vancomycin in a home-infusion setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, multi-center, phase 4 study. The overall goals of this
      study are to compare intravenous (IV) daptomycin and IV vancomycin administered in a home
      infusion setting for the treatment of cSSSI due to Gram-positive bacteria in participants who
      are prescribed vancomycin for 7-14 days and who are planning to receive vancomycin in a home
      infusion setting. Study objectives include evaluation of clinical and resource utilization
      endpoints and economic analysis from the perspective of the home infusion provider.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time Spent (Minutes) for Home Infusion Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>Each participant is counted once per category. Avg=average; Admin=administer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Antibiotic Therapy Duration (in Days) Per Participant for Home Infusion Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>The mean duration in home-infusion antibiotic therapy per participant is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Nurse Visits or Consultations Per Participant for Home Infusion Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>Each participant is counted once per category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With at Least 1 Unscheduled Nursing Visit During Home Infusion Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With at Least One Pharmacist Consultation During Home Infusion Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reasons for Nurse Visits During Home Infusion Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>The reason for a participant's nurse visit is presented. There may be more than one reason for nurse visits per participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reasons for Pharmacist Consultations During Home Infusion Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>The reason for a participant's pharmacist consultation is presented. There may be more than one reason for pharmacist consultations per participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Treatment Goals Met at End of Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>Treatment goals included: 1. Elimination of infection/achieved desired response. 2. Laboratory values were within normal limits or improved indicating progress toward therapy goal. 3. Pain was controlled. 4. Participant did not have catheter site complications (eg,infection, loss of patency). 5. Participant had no knowledge deficits related to administration, equipment use, side effects and waste disposal. 6. Participant had no side effects, adverse drug reactions and/or drug or food interactions. 7. Signs and symptoms of infection did improve or resolve. 8. Participant was compliant with IV therapy 9. Successfully completed therapy without interruptions, unexpected hospitalizations. 10. Participant continued on an oral antibiotic. 11. Participant continued on an IV antibiotic.
Each participant's percentage was derived from number of treatment goals achieved out of a maximum of 11 goals. Reported percentage below is the average of all participants' percentage of goals met by arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least 1 Intervention Related to Complicated Skin or Skin Structure Infection (cSSSI) During Home Infusion Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>Type of interventions include Intravenous (IV) line replacement, IV line removal, IV line placement (post study therapy), Incision and drainage (wound), Incision and drainage (line), Debridement, Declotting procedure, and Blood draw.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Interventions Per Participant During Home Infusion Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>Type of interventions include IV line replacement, IV line removal, IV line placement (post study therapy), incision and drainage (wound), incision and drainage (line), debridement, declotting procedure, and blood draw.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Intervention Types During Home Infusion Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>There may be more than one type of intervention per participant. A participant is counted only once for each category even if they had several instances of a given intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Had More Than 1 Laboratory Assessment During Home Infusion Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>Laboratory assessments include serum creatinine, creatine phosphokinase (CPK), and Vancomycin trough.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Laboratory Assessments Per Participant During Home Infusion Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>Laboratory assessments include serum creatinine, creatine phosphokinase (CPK), and vancomycin trough.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Laboratory Assessment Types During Home Infusion Therapy</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>There may be more than one type of laboratory assessment per participant. A participant is counted only once for each category. Laboratory assessments include serum creatinine, creatine phosphokinase (CPK), and vancomycin trough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economic Outcomes in United States (US) Dollars for Home Infusion Therapy Per Participant</measure>
    <time_frame>Day 1 up to Day 14</time_frame>
    <description>Total Heartland costs per participant were derived by summing the costs of drug, pharmacy services/supplies and nursing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Complicated Skin or Skin Structure Infection</condition>
  <arm_group>
    <arm_group_label>Daptomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <arm_group_label>Daptomycin</arm_group_label>
    <other_name>Cubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Complicated skin or skin structure infection (cSSSI)

          -  Intravenous vancomycin home infusion ordered for 7-14 days

        Exclusion Criteria:

          -  Pregnant or lactating female

          -  Concurrently receiving other systemic antibiotics with gram positive activity

          -  Known or suspected allergy or hypersensitivity to daptomycin or vancomycin

          -  Known or suspected vancomycin-resistant enterococci (VRE)

          -  Known or suspected osteomyelitis, pneumonia, bacteremia, endocarditis, or urinary
             tract infection

          -  Known or suspected human immunodeficiency virus (HIV), cancer, or autoimmune disease
             such as lupus

          -  Receiving systemic concomitant immunosuppressive agents such as chemotherapy,
             corticosteroids, tacrolimus, sirolimus, or cyclosporine, during the duration of the
             study

          -  Requirement for non-study gram positive systemic antibiotics

          -  Known to be allergic or intolerant to intravenous vancomycin or daptomycin

          -  Participants with known or suspected creatinine clearance (CLcr) &lt; 30 milliliters per
             minute (mL/min)

          -  In skilled nursing facility

          -  In hospice or admission to hospice is planned
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Bokesch, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cubist Pharmaceuticals LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heartland I.V. Care</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland I.V. Care</name>
      <address>
        <city>Roseville</city>
        <state>Minnesota</state>
        <zip>55113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland I.V. Care</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NationsMed Clinical Research, Inc.</name>
      <address>
        <city>Stafford</city>
        <state>Texas</state>
        <zip>77477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2010</study_first_submitted>
  <study_first_submitted_qc>August 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2010</study_first_posted>
  <results_first_submitted>April 5, 2013</results_first_submitted>
  <results_first_submitted_qc>April 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2015</results_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Daptomycin</title>
          <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
        </group>
        <group group_id="P2">
          <title>Vancomycin</title>
          <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All study participants</population>
      <group_list>
        <group group_id="B1">
          <title>Daptomycin</title>
          <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
        </group>
        <group group_id="B2">
          <title>Vancomycin</title>
          <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.55" spread="14.387"/>
                    <measurement group_id="B2" value="56.78" spread="19.366"/>
                    <measurement group_id="B3" value="57.665" spread="16.8765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time Spent (Minutes) for Home Infusion Therapy</title>
        <description>Each participant is counted once per category. Avg=average; Admin=administer.</description>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent (Minutes) for Home Infusion Therapy</title>
          <description>Each participant is counted once per category. Avg=average; Admin=administer.</description>
          <population>All study participants.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total antibiotic therapy duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.7" spread="326.07"/>
                    <measurement group_id="O2" value="1430.1" spread="1331.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total time to administer drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6" spread="132.66"/>
                    <measurement group_id="O2" value="1001.7" spread="696.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Avg time per day to administer drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.64" spread="8.221"/>
                    <measurement group_id="O2" value="127.78" spread="59.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Avg time to admin drug per infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.64" spread="8.221"/>
                    <measurement group_id="O2" value="95.81" spread="23.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total caregiver time to admin drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.8" spread="494.86"/>
                    <measurement group_id="O2" value="1336" spread="1527.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Avg caregiver time per day to admin drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.66" spread="21.376"/>
                    <measurement group_id="O2" value="148.66" spread="174.709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Avg caregiver time per infusion to admin drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.66" spread="21.376"/>
                    <measurement group_id="O2" value="124.25" spread="175.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total nursing time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393.0" spread="229.34"/>
                    <measurement group_id="O2" value="404.2" spread="321.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Avg nursing time per visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.25" spread="17.920"/>
                    <measurement group_id="O2" value="85.80" spread="23.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Avg nursing time per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.97" spread="17.759"/>
                    <measurement group_id="O2" value="87.79" spread="25.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total time for pharmacist consultations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" spread="29.59"/>
                    <measurement group_id="O2" value="55.3" spread="35.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Antibiotic Therapy Duration (in Days) Per Participant for Home Infusion Therapy</title>
        <description>The mean duration in home-infusion antibiotic therapy per participant is presented.</description>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Antibiotic Therapy Duration (in Days) Per Participant for Home Infusion Therapy</title>
          <description>The mean duration in home-infusion antibiotic therapy per participant is presented.</description>
          <population>All study participants.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="6.05"/>
                    <measurement group_id="O2" value="11.0" spread="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Nurse Visits or Consultations Per Participant for Home Infusion Therapy</title>
        <description>Each participant is counted once per category.</description>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Nurse Visits or Consultations Per Participant for Home Infusion Therapy</title>
          <description>Each participant is counted once per category.</description>
          <population>All study participants.</population>
          <units>Visits or Consultations per Participant</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number of nursing visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="3.90"/>
                    <measurement group_id="O2" value="5.0" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total number of scheduled nursing visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.91"/>
                    <measurement group_id="O2" value="4.4" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total number of unscheduled nursing visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.91" spread="4.0"/>
                    <measurement group_id="O2" value="1.24" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total number of pharmacist consultations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="4.22"/>
                    <measurement group_id="O2" value="9.6" spread="5.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least 1 Unscheduled Nursing Visit During Home Infusion Therapy</title>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>Number of Participants Analyzed based on number of participants with at least one nurse visit/pharmacist consultation within each treatment group results in 39 participants analyzed for the Daptomycin ARM group for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least 1 Unscheduled Nursing Visit During Home Infusion Therapy</title>
          <population>Number of Participants Analyzed based on number of participants with at least one nurse visit/pharmacist consultation within each treatment group results in 39 participants analyzed for the Daptomycin ARM group for this Outcome Measure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least One Pharmacist Consultation During Home Infusion Therapy</title>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Pharmacist Consultation During Home Infusion Therapy</title>
          <population>All study participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reasons for Nurse Visits During Home Infusion Therapy</title>
        <description>The reason for a participant’s nurse visit is presented. There may be more than one reason for nurse visits per participant.</description>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Reasons for Nurse Visits During Home Infusion Therapy</title>
          <description>The reason for a participant’s nurse visit is presented. There may be more than one reason for nurse visits per participant.</description>
          <population>All study participants.</population>
          <units>Reason Cited</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Laboratory assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant/Caregiver teaching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Site/Catheter care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reasons for Pharmacist Consultations During Home Infusion Therapy</title>
        <description>The reason for a participant’s pharmacist consultation is presented. There may be more than one reason for pharmacist consultations per participant.</description>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Reasons for Pharmacist Consultations During Home Infusion Therapy</title>
          <description>The reason for a participant’s pharmacist consultation is presented. There may be more than one reason for pharmacist consultations per participant.</description>
          <population>All study participants.</population>
          <units>Reason Cited</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Development/revision of care plan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Review of written reports of participant status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Review of related labs and other studies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Communication - participant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Communication - prescriber</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Communication - home care nurse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Communication - integration of new information</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Treatment Goals Met at End of Therapy</title>
        <description>Treatment goals included: 1. Elimination of infection/achieved desired response. 2. Laboratory values were within normal limits or improved indicating progress toward therapy goal. 3. Pain was controlled. 4. Participant did not have catheter site complications (eg,infection, loss of patency). 5. Participant had no knowledge deficits related to administration, equipment use, side effects and waste disposal. 6. Participant had no side effects, adverse drug reactions and/or drug or food interactions. 7. Signs and symptoms of infection did improve or resolve. 8. Participant was compliant with IV therapy 9. Successfully completed therapy without interruptions, unexpected hospitalizations. 10. Participant continued on an oral antibiotic. 11. Participant continued on an IV antibiotic.
Each participant’s percentage was derived from number of treatment goals achieved out of a maximum of 11 goals. Reported percentage below is the average of all participants’ percentage of goals met by arm.</description>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Treatment Goals Met at End of Therapy</title>
          <description>Treatment goals included: 1. Elimination of infection/achieved desired response. 2. Laboratory values were within normal limits or improved indicating progress toward therapy goal. 3. Pain was controlled. 4. Participant did not have catheter site complications (eg,infection, loss of patency). 5. Participant had no knowledge deficits related to administration, equipment use, side effects and waste disposal. 6. Participant had no side effects, adverse drug reactions and/or drug or food interactions. 7. Signs and symptoms of infection did improve or resolve. 8. Participant was compliant with IV therapy 9. Successfully completed therapy without interruptions, unexpected hospitalizations. 10. Participant continued on an oral antibiotic. 11. Participant continued on an IV antibiotic.
Each participant’s percentage was derived from number of treatment goals achieved out of a maximum of 11 goals. Reported percentage below is the average of all participants’ percentage of goals met by arm.</description>
          <population>All study participants.</population>
          <units>Percentage of Goals Met</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.98" spread="10.842"/>
                    <measurement group_id="O2" value="75.21" spread="11.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least 1 Intervention Related to Complicated Skin or Skin Structure Infection (cSSSI) During Home Infusion Therapy</title>
        <description>Type of interventions include Intravenous (IV) line replacement, IV line removal, IV line placement (post study therapy), Incision and drainage (wound), Incision and drainage (line), Debridement, Declotting procedure, and Blood draw.</description>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least 1 Intervention Related to Complicated Skin or Skin Structure Infection (cSSSI) During Home Infusion Therapy</title>
          <description>Type of interventions include Intravenous (IV) line replacement, IV line removal, IV line placement (post study therapy), Incision and drainage (wound), Incision and drainage (line), Debridement, Declotting procedure, and Blood draw.</description>
          <population>All study participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Had at least 1 intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had no intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Interventions Per Participant During Home Infusion Therapy</title>
        <description>Type of interventions include IV line replacement, IV line removal, IV line placement (post study therapy), incision and drainage (wound), incision and drainage (line), debridement, declotting procedure, and blood draw.</description>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Interventions Per Participant During Home Infusion Therapy</title>
          <description>Type of interventions include IV line replacement, IV line removal, IV line placement (post study therapy), incision and drainage (wound), incision and drainage (line), debridement, declotting procedure, and blood draw.</description>
          <population>All study participants.</population>
          <units>Interventions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.30"/>
                    <measurement group_id="O2" value="1.5" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Intervention Types During Home Infusion Therapy</title>
        <description>There may be more than one type of intervention per participant. A participant is counted only once for each category even if they had several instances of a given intervention.</description>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Intervention Types During Home Infusion Therapy</title>
          <description>There may be more than one type of intervention per participant. A participant is counted only once for each category even if they had several instances of a given intervention.</description>
          <population>All study participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IV line replacement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incision and drainage (wound)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>De-clotting procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Had More Than 1 Laboratory Assessment During Home Infusion Therapy</title>
        <description>Laboratory assessments include serum creatinine, creatine phosphokinase (CPK), and Vancomycin trough.</description>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Had More Than 1 Laboratory Assessment During Home Infusion Therapy</title>
          <description>Laboratory assessments include serum creatinine, creatine phosphokinase (CPK), and Vancomycin trough.</description>
          <population>All study participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Laboratory Assessments Per Participant During Home Infusion Therapy</title>
        <description>Laboratory assessments include serum creatinine, creatine phosphokinase (CPK), and vancomycin trough.</description>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Laboratory Assessments Per Participant During Home Infusion Therapy</title>
          <description>Laboratory assessments include serum creatinine, creatine phosphokinase (CPK), and vancomycin trough.</description>
          <population>All study participants.</population>
          <units>Assessments</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.19"/>
                    <measurement group_id="O2" value="2.8" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Laboratory Assessment Types During Home Infusion Therapy</title>
        <description>There may be more than one type of laboratory assessment per participant. A participant is counted only once for each category. Laboratory assessments include serum creatinine, creatine phosphokinase (CPK), and vancomycin trough</description>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Laboratory Assessment Types During Home Infusion Therapy</title>
          <description>There may be more than one type of laboratory assessment per participant. A participant is counted only once for each category. Laboratory assessments include serum creatinine, creatine phosphokinase (CPK), and vancomycin trough</description>
          <population>All study participants.</population>
          <units>Assessments</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vancomycin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Economic Outcomes in United States (US) Dollars for Home Infusion Therapy Per Participant</title>
        <description>Total Heartland costs per participant were derived by summing the costs of drug, pharmacy services/supplies and nursing.</description>
        <time_frame>Day 1 up to Day 14</time_frame>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Economic Outcomes in United States (US) Dollars for Home Infusion Therapy Per Participant</title>
          <description>Total Heartland costs per participant were derived by summing the costs of drug, pharmacy services/supplies and nursing.</description>
          <population>All study participants.</population>
          <units>US Dollars</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Drug Costs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2762.37" spread="1446.140"/>
                    <measurement group_id="O2" value="107.14" spread="69.264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pharmacy Service and Supplies Costs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="641.25" spread="247.263"/>
                    <measurement group_id="O2" value="596.25" spread="278.472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nursing Costs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="637.63" spread="404.868"/>
                    <measurement group_id="O2" value="583.02" spread="475.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Heartland Costs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3956.25" spread="1781.020"/>
                    <measurement group_id="O2" value="1273.02" spread="667.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency Room (ER) Visit Costs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1660.31" spread="761.630"/>
                    <measurement group_id="O2" value="1518" spread="533.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost Work Costs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3729.13" spread="3753.586"/>
                    <measurement group_id="O2" value="3635.60" spread="6404.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Daptomycin</title>
          <description>500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted.</description>
        </group>
        <group group_id="E2">
          <title>Vancomycin</title>
          <description>Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first publication is initiated by Cubist. If First Publication not published within 1 year of Study conclusion or termination, Investigator has right to publish and disclose the Data. Prior to any submission for publication, presentation, or communication of results or information arising from the Study, Investigator shall provide Cubist at least 90 days for review and comment upon the manuscript or other material for such publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated prematurely.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vice President, Clinical Research</name_or_title>
      <organization>Cubist Pharmaceuticals</organization>
      <phone>781-860-8318</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

